Brokerages Set Smith & Nephew plc (LON:SN) Price Target at GBX 1,185.86

Shares of Smith & Nephew plc (LON:SN) have earned an average rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is GBX 1,185.86.

SN has been the topic of several research reports. Berenberg Bank reaffirmed a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a research note on Friday, May 1st. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and set a GBX 1,350 price objective for the company. in a report on Thursday, May 7th. Finally, UBS Group reaffirmed a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research note on Tuesday, May 5th.

Smith & Nephew Stock Performance

LON SN opened at GBX 1,122 on Thursday. The company has a 50 day moving average price of GBX 1,197.24 and a two-hundred day moving average price of GBX 1,243.12. The firm has a market cap of £12.30 billion, a PE ratio of 40.40, a P/E/G ratio of 0.46 and a beta of 0.67. The company has a debt-to-equity ratio of 62.90, a current ratio of 2.57 and a quick ratio of 0.84.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.